A detailed history of Commonwealth Equity Services, LLC transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 10,564 shares of ADMA stock, worth $223,745. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,564
Previous 15,710 32.76%
Holding current value
$223,745
Previous $176,000 19.89%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$11.21 - $20.03 $57,686 - $103,074
-5,146 Reduced 32.76%
10,564 $211,000
Q2 2024

Jul 31, 2024

BUY
$5.98 - $11.18 $17,641 - $32,981
2,950 Added 23.12%
15,710 $176,000
Q1 2024

Apr 29, 2024

SELL
$4.4 - $6.74 $15,840 - $24,264
-3,600 Reduced 22.0%
12,760 $84,000
Q3 2023

Oct 23, 2023

BUY
$3.47 - $4.61 $21,687 - $28,812
6,250 Added 61.82%
16,360 $59,000
Q1 2023

May 11, 2023

SELL
$3.01 - $3.87 $5,393 - $6,935
-1,792 Reduced 15.06%
10,110 $33,000
Q4 2022

Feb 07, 2023

BUY
$2.47 - $3.88 $4,426 - $6,952
1,792 Added 17.73%
11,902 $46,000
Q3 2022

Nov 14, 2022

BUY
$2.03 - $2.86 $20,523 - $28,914
10,110 New
10,110 $24,000
Q2 2022

Jul 19, 2022

SELL
$1.43 - $2.2 $37,194 - $57,222
-26,010 Closed
0 $0
Q1 2022

May 04, 2022

BUY
$1.28 - $1.83 $3,840 - $5,490
3,000 Added 13.04%
26,010 $47,000
Q4 2021

Jan 31, 2022

SELL
$1.09 - $1.66 $2,180 - $3,320
-2,000 Reduced 8.0%
23,010 $32,000
Q3 2021

Oct 29, 2021

SELL
$1.13 - $1.65 $5,649 - $8,250
-5,000 Reduced 16.66%
25,010 $28,000
Q2 2021

Aug 11, 2021

SELL
$1.51 - $2.07 $30,719 - $42,112
-20,344 Reduced 40.4%
30,010 $48,000
Q1 2021

May 04, 2021

BUY
$1.67 - $2.95 $84,091 - $148,544
50,354 New
50,354 $88,000

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $4.16B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.